Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile. Participants will receive either a periocular injection of AIV007 or intravitreal injection of Eylea (control arm) to the study eye and return to the clinic monthly for safety and efficacy observations and/or continued treatment. Participants may receive additional treatment(s) if they meet specified criteria.

NCT Number	NCT07557121
Lead Sponsor	AiViva BioPharma, Inc. Collaborators: ClinDatrix, Inc.
Conditions	Neovascular (Wet) Age-Related Macular Degeneration
Enrollment	35 participants
Start Date	2026-07-01
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-08-23 (estimated)
Updated on ClinicalTrials.gov	2026-04-29